How many clinical trials has dulaglutide completed?

Dulaglutide has been evaluated in 73+ registered clinical trials globally. The most significant are the AWARD series (5 Phase 3 trials, ~6,000 patients) and REWIND (9,901 patients with cardiovascular outcomes). This extensive trial portfolio is unusual among peptide therapeutics and contributes to its A-grade evidence rating.

Does dulaglutide prevent heart attacks?

Dulaglutide reduces the risk of major adverse cardiovascular events (MACE—heart attack, stroke, cardiovascular death) by approximately 12% based on the REWIND trial. This doesn't mean it prevents all heart attacks, but it meaningfully lowers cardiovascular risk in people with type 2 diabetes and existing heart disease or risk factors.

What's the most common side effect of dulaglutide?

Nausea is the most frequently reported side effect, occurring in 20–30% of patients, especially at treatment initiation. It typically improves over 1–2 weeks. Vomiting, diarrhea, and constipation also occur but are less common. Serious side effects like pancreatitis are rare (<0.1%).

How does dulaglutide's evidence compare to newer GLP-1s like semaglutide?

Dulaglutide has longer-term cardiovascular outcomes data (REWIND, 5.4 years) and more diverse trial populations. Semaglutide shows slightly greater weight loss but has smaller and less representative cardiovascular trials. Both are well-evidenced; choice depends on individual factors like injection preference and comorbidities.

Is dulaglutide safe for long-term use?

Yes. REWIND followed patients for over 5 years, demonstrating sustained benefit and a consistent safety profile. The most common side effects (nausea, GI upset) are transient. Serious adverse events occur at low rates comparable to placebo in large trials.

Dulaglutide Research Evidence: Clinical Trials & Studies

Q: How does dulaglutide's evidence compare to newer GLP-1s like semaglutide?

Dulaglutide has longer-term cardiovascular outcomes data (REWIND, 5.4 years) and more diverse trial populations. Semaglutide shows slightly greater weight loss but has smaller and less representative cardiovascular trials. Both are well-evidenced; choice depends on individual factors like injection preference and comorbidities.

Q: Is dulaglutide safe for long-term use?

Yes. REWIND followed patients for over 5 years, demonstrating sustained benefit and a consistent safety profile. The most common side effects (nausea, GI upset) are transient. Serious adverse events occur at low rates comparable to placebo in large trials.

Dulaglutide is an FDA-approved GLP-1 receptor agonist with robust clinical evidence supporting its use in type 2 diabetes and weight management. The compound has been evaluated in over 73 clinical trials globally, generating an A-grade evidence base that spans efficacy, safety, cardiovascular outcomes, and metabolic effects. Unlike many peptide therapeutics still in preclinical stages, dulaglutide's research portfolio includes large randomized controlled trials, real-world effectiveness studies, and long-term safety follow-ups. This deep-dive breaks down what the research actually shows, how it compares to alternatives, and where evidence gaps still exist.

The Dulaglutide Clinical Trial Landscape

Dulaglutide's journey from development to approval was anchored in one of the most comprehensive clinical trial programs in modern diabetes research. With 73 registered clinical trials across multiple indications and populations, the compound has been tested in diverse patient groups—from treatment-naïve individuals to those with advanced cardiovascular disease.

The regulatory approvals tell the story: FDA approval in 2014, EMA authorisation in 2014, and Health Canada approval in 2015 all came after Phase 3 trial data demonstrated consistent benefits. This multi-regulator consensus is rare and signals strong evidence.

The AWARD Trial Series: Foundational Evidence

Dulaglutide's core efficacy evidence comes from the AWARD (Assessment of Weekly AdministRation of LY2189265) trial series—five Phase 3 randomized controlled trials published between 2012 and 2015. These studies form the backbone of what we know about the compound's effect on blood glucose and A1C reduction.

AWARD-1 enrolled 1,096 patients with type 2 diabetes inadequately controlled on metformin and tested dulaglutide against insulin glargine. Results showed A1C reductions of 1.4–1.7% depending on dulaglutide dose, comparable to insulin, with significantly lower hypoglycemia risk. The weekly dosing regimen proved more convenient than daily insulin injections—an important practical advantage.

AWARD-2 compared dulaglutide to sitagliptin (a DPP-4 inhibitor) in 1,142 patients. Dulaglutide demonstrated superior A1C reduction (1.3–1.8% vs. 0.7% for sitagliptin), establishing superiority over a major drug class and justifying dulaglutide's positioning as a more potent glucose-lowering agent.

AWARD-3 involved 1,551 patients and pitted dulaglutide against exenatide—another GLP-1 agonist but with a different pharmacokinetic profile. Dulaglutide achieved greater A1C reduction (1.3–1.8% vs. 1.1% for exenatide) and produced greater weight loss, suggesting benefits from its longer half-life and once-weekly formulation.

AWARD-4 and AWARD-5 tested dulaglutide as add-on therapy in combination regimens. These trials validated dulaglutide's role not just as monotherapy but as a component of multi-drug diabetes management—mirroring real-world practice patterns.

Cardiovascular Outcomes: The REWIND Trial

While glucose-lowering is important, the real game-changer for GLP-1 agonists came with cardiovascular outcomes research. The REWIND trial (Researching Cardiovascular Events with a Weekly Incretin Therapy) enrolled 9,901 patients with type 2 diabetes and either established cardiovascular disease or cardiovascular risk factors.

Published in 2019, REWIND demonstrated that dulaglutide reduced major adverse cardiovascular events (MACE) by 12% compared to placebo. The composite outcome included heart attack, stroke, and cardiovascular death. This wasn't a marginal benefit—it was statistically significant and clinically meaningful. Importantly, dulaglutide also reduced the risk of hospitalization for heart failure, a growing concern in diabetes care.

REWIND enrolled a real-world population: 31% had prior myocardial infarction, 16% had prior stroke, and 70% were over age 60. This broadens the relevance of the findings beyond younger, healthier trial volunteers. The median follow-up was 5.4 years, providing long-term safety and efficacy data—something many novel peptides lack.

Weight Loss and Metabolic Effects

Beyond glucose control, dulaglutide consistently produces weight loss—a secondary but clinically relevant outcome. Across the AWARD trials, patients experienced weight reductions of 2–3 kg on average, with some dose-response correlation.

In REWIND, dulaglutide-treated patients lost approximately 1.5 kg more than placebo over the 5-year period. While modest compared to newer agents like semaglutide, this sustained weight loss contributes to metabolic improvement and cardiovascular benefit.

The mechanism involves multiple pathways: delayed gastric emptying, increased satiety signaling, and improved insulin secretion. Animal and mechanistic studies suggest GLP-1 agonists may also reduce hepatic steatosis and improve lipid profiles, though these effects are less pronounced than glucose-lowering.

Safety and Tolerability: The Full Picture

No therapy is without risk. Dulaglutide's safety profile, examined across 73 trials, reveals both reassuring patterns and important cautions.

Gastrointestinal Effects

Nausea is the most common adverse effect, occurring in 20–30% of patients in trials—higher at initiation and lower with dose escalation. REWIND reported nausea in 25.7% of dulaglutide recipients vs. 8.5% with placebo. This is mechanism-based (GLP-1 acts on central satiety centers) and generally manageable through slower dose titration.

Vomiting and diarrhea occur less frequently (5–10%) and often improve over time. Constipation, paradoxically, is also documented in some patients.

Pancreatitis and Pancreatic Safety

Early concerns about acute pancreatitis with GLP-1 agonists have not materialized in large trials. REWIND reported pancreatitis rates of 0.1% in both dulaglutide and placebo groups, providing reassurance. However, dulaglutide carries a black box warning (inherited from the GLP-1 class) regarding medullary thyroid carcinoma risk based on rodent studies—a concern that hasn't manifested in human trials but remains a theoretical consideration.

Hypoglycemia

When used alone, dulaglutide causes minimal hypoglycemia. AWARD-1 demonstrated hypoglycemia rates of <1% with dulaglutide monotherapy, much lower than insulin. Combined with other glucose-lowering agents (especially sulfonylureas or insulin), hypoglycemia risk increases, requiring dose adjustments.

Comparison to Other GLP-1 Agonists: Where Dulaglutide Stands

Dulaglutide is one of several GLP-1 agonists on the market. How does the evidence compare?

vs. Exenatide (Byetta, Bydureon): AWARD-3 showed dulaglutide superior in A1C reduction and weight loss, likely due to longer half-life and once-weekly dosing. Exenatide requires twice-daily dosing (or weekly for extended-release formulations).

vs. Semaglutide (Ozempic, Wegovy): Semaglutide is newer and shows slightly greater weight loss in head-to-head trials, but dulaglutide has longer-term cardiovascular outcomes data (REWIND). Semaglutide's cardiovascular outcomes trial (SUSTAIN-6) is smaller and less representative of general diabetic populations.

vs. Liraglutide (Victoza, Saxenda): Liraglutide requires daily injections; dulaglutide's weekly format improves adherence. Both show similar A1C reduction, but dulaglutide has more robust cardiovascular data.

Dulaglutide's key advantage is not superiority in any single outcome, but rather the combination of proven cardiovascular benefit (REWIND), long-term safety data, once-weekly convenience, and broad regulatory approval—making it a well-evidenced, practical option.

Evidence Gaps and Limitations

Even with 73 trials, important gaps remain:

1. Longer-Term Durability: REWIND followed patients for 5.4 years—excellent by diabetes standards, but we lack 10+ year data on sustained efficacy and safety.

2. Real-World Adherence: RCTs show what's possible under controlled conditions; real-world dulaglutide effectiveness studies (separate from efficacy trials) are emerging but still limited compared to older agents.

3. Comparison to GLP-1/GIP Agonists: Newer dual-action agents (like tirzepatide) are entering the market; direct comparative trials with dulaglutide are ongoing but not yet published.

4. Renal and Hepatic Populations: Most trials excluded advanced kidney or liver disease; evidence in these vulnerable groups is indirect.

5. Mechanistic Understanding: While we know dulaglutide lowers glucose and reduces MACE, the biological pathways driving cardiovascular benefit beyond glucose control remain incompletely understood—suggesting room for future research into optimizing use.

Evidence Grade: Why "A"

Dulaglutide earns an A-grade evidence rating based on:

Study design: 73 trials including large, multi-center, double-blind RCTs
Primary outcomes: Consistent A1C reduction across diverse populations
Secondary outcomes: Proven cardiovascular benefit in REWIND (9,901 patients, 5.4 years)
Safety: Long-term adverse event monitoring with transparent reporting
Regulatory alignment: Approved by FDA, EMA, and Health Canada with consistent findings

This contrasts sharply with many peptide therapeutics, which rest on animal studies or Phase 2 data.

Practical Takeaway for Consumers

If you're considering dulaglutide or researching GLP-1 options, the evidence tells a clear story: it's effective for blood sugar control, produces modest weight loss, protects the heart, and carries a manageable safety profile dominated by transient GI effects. It's not a miracle drug—A1C reductions of 1–2% are meaningful but require lifestyle changes to maximize benefit. The once-weekly injection appeals to many. But it's important to discuss with a healthcare provider whether it fits your specific situation, as individual responses vary and comorbidities influence choice.

For researchers and clinicians, dulaglutide represents a well-characterized therapy with proven real-world applicability—useful as a reference point for evaluating newer peptide therapeutics against.

Related Peptide Therapies

If you're exploring the broader GLP-1 landscape, consider reading about semaglutide, liraglutide, and tirzepatide—each with distinct evidence profiles and clinical niches.

Understanding GLP-1 receptor agonists and pharmacokinetics also enriches how you interpret trial data.

Dulaglutide Research Evidence: What the Clinical Trials Show